Workday’s Kazmaier sells $1.2m in shares By Investing.com

Workday President Gerrit Kazmaier sold 9,356 shares on Apr 7 for ~$1.2M at $128.39 and 12,270 shares on Apr 5 for ~$1.6M at $132.26 to cover taxes; he now directly owns 165,074 shares (161,956 RSUs). Workday reported Q4 FY2026 that met revenue and beat earnings with improved operating margin, yet shares trade at $127.51 (near a 52-week low of $117.76 and down ~45% over six months) and the stock faces downward analyst pressure: DA Davidson cut its target to $125 from $250, BMO to $182 from $204, and Freedom Capital to $210 from $280. Company fundamentals include a $32.8B market cap, more cash than debt, a Fair Value estimate of $202.59 from InvestingPro, a CEO equity award of 437,602 RSUs vesting over four years, and a new customer win at Fairview Health Services.

Analysis

Workday sits at the intersection of three forces: enterprise buyers delaying platform migrations until AI features are proven, vendors racing to field agentic capabilities, and investors repricing growth risk into multiples. That dynamic favors vendors who can monetize incremental AI features through attach rates and seat expansions rather than large up-front migrations; if Workday can keep NRR above 100% while introducing paid AI modules, its recovery will be more margin-accretive than consensus models assume.

Margin improvement driven by reduced hiring is a short-duration lever — reopening hiring to pursue AI parity or to accelerate product roadmaps will bite into operating margin within 2–9 quarters. Separately, multi-year equity programs aimed at retention create lumpy dilution around vesting cliffs; model a 1–2% annual share-count creep for material awards and stress-test EPS under that path vs a base case with stable shares.

Sell-side cuts have likely compressed implied upside and inflated volatility; that creates asymmetric option entry points for patient capital. The market appears to be pricing a prolonged secular slowdown in AI-driven demand — a scenario that allows a measured, catalyst-based re-rating if the company reports sequential acceleration in paid AI bookings or beats NRR/ARR retention metrics over two consecutive quarters (a 3–12 month catalyst window). The contrarian case: modest product wins and steady cross-sell can restore multiple expansion without a return to prior hypergrowth, delivering >40% upside over 12–24 months if execution is stable.

Key Decisions for Investors

• Initiate a tactical long position in WDAY (3–5% NAV) with a 12–18 month horizon. Target +50–70% total return on recovery to normalized multiple; hard stop -30% to protect against an execution or AI-competition shock.
• Buy a calendar call spread to express asymmetric upside with defined risk: buy WDAY Jan 19 2028 130 call / sell WDAY Jan 19 2027 130 call (rollable). Use this if you want gamma exposure to a 6–18 month re-acceleration in paid AI modules; max loss = debit paid, upside uncapped into 2028.
• Pair trade to hedge macro/software multiple risk: long WDAY equal-$ notional / short ADP equal-$ notional for 9–12 months. This isolates product re-rating vs payroll macro — target +40% on the pair if Workday outperforms ADP on NRR/ARR, stop if pair underperforms by 20%.
• Event-driven option play: buy WDAY 6–9 month OTM calls sized for 1–2% NAV to capture upside around two potential catalysts (sequential ARR retention beats or announcement of monetized AI agent features). Risk = option premium; reward asymmetry if either catalyst prints.